A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
GY025 is open to accrual to the Phase II portion of the study, effective September 3, 2025.
